Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
Source: SeekingAlpha
2026-03-19 07:44:26 ET
More on Pfizer, Astellas Pharma ADR
- Pfizer: I'm Still Expecting A Massive Rebound
- Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
- Pfizer: Cheap For A Reason
- TrumpRx drug prices aren't the lowest as president claims - report
- FTC monitoring how Big Pharma reacts to upcoming patent cliffs, official says
Read the full article on Seeking Alpha
For further details see:
Pfizer posts late-stage trial win for Talzenna plus Xtandi in new prostate cancer indication
Astellas Pharma Inc.
NASDAQ: ALPMF
ALPMF Trading
6.03% G/L:
$14.50 Last:
3,858 Volume:
$13.68 Open:
ALPMF Latest News
$28,999,226,915
1,808,873,137
N/A
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
